NasdaqGS · Biotechnology

Madrigal Pharmaceuticals (MDGL)

Stock, pipeline and biotech catalyst intelligence

Analyst view

Strong Buy+31.2%

$678.06 average target

$516.74-2.35 (-0.5%)Latest market snapshot · Yahoo Finance

Market cap$11.94B

Cash$838.8M

Quarterly burn$23.3M

Pipeline assets3

Short float10.0%

Latest coverage

News & Press Releases

External sources

Aug 20, 2026

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire

Aug 15, 2026

Madrigal’s Rezdiffra Hits $1.3B Run Rate as MASH Pipeline ExpandsMarketBeat

Aug 12, 2026

Madrigal Appoints John C. Reed, M.D., Ph.D., to its Board of DirectorsGlobeNewswire

Continue with BioPharma ProUnlock 2 more recent stories and press releases.

Unlock Pro

Company profile

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.

Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.

Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.